Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ).
JCR Pharmaceuticals released materials for its FY2025 results briefing session, outlining financial data and development progress, while emphasizing that the figures are rounded and may contain minor numerical discrepancies. The company stressed that the briefing includes forward-looking descriptions that are subject to significant risks and uncertainties, and that any information on pharmaceuticals and medical devices, including those under development, is not intended as advertising or medical advice, underscoring a cautious stance toward investor expectations and regulatory compliance.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen900.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a Japan-based biopharmaceutical company listed on the Tokyo Stock Exchange Prime Market under securities code 4552. The company focuses on the research, development, and manufacture of pharmaceuticals and medical devices, including products for rare and intractable diseases.
Average Trading Volume: 551,901
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen69.05B
See more insights into 4552 stock on TipRanks’ Stock Analysis page.